Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ed Natoli"'
Autor:
Linda Crew, Zeyu Peng, Thomas O'Neill, James L. Boyer, Mark Z. Ma, Michael T. Murphy, Lawrence J. Thomas, Jeff Weidlick, Colleen Patterson, Russell A. Hammond, Diego Alvarado, Anna Wasiuk, April R. Baronas, Joel Goldstein, Laura Mills-Chen, Tibor Keler, Andrea Crocker, Jay S. Lillquist, Jenifer Widger, Laura Vitale, Ed Natoli, Collin Xia, Henry C. Marsh, Hugh Davis
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A833-A833
BackgroundActivation of the ITIM-bearing ILT4/LILRB2 receptor by its cognate ligands (HLA-G and HLA Class I) has been postulated as a resistance mechanism for checkpoint blockade of PD-1 and CTLA-4. Dual inhibition of receptors that suppress myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83a46fa79c93a7939d7fedcd55b405b1
https://doi.org/10.1136/jitc-2021-sitc2021.798
https://doi.org/10.1136/jitc-2021-sitc2021.798
Autor:
Carol B. Donovan, Robbin Alpert, Ronald P. Gladue, Eileen A. Elliott, Vahe Bedian, Richard M. Shepard, Ed Natoli, Timothy Joseph Paradis, Joe Gardner, Robin T. Nelson, Susan Cole
Publikováno v:
Cancer immunology, immunotherapy : CII. 60(7)
CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In this study, we demonstrate the in vitro properties and in vivo efficacious a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e45b8f396af57db610f46ae460ad04b
https://pubmed.ncbi.nlm.nih.gov/21479995
https://pubmed.ncbi.nlm.nih.gov/21479995